{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:43:16Z","timestamp":1769514196561,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2007,2,17]],"date-time":"2007-02-17T00:00:00Z","timestamp":1171670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2007,2,17]],"date-time":"2007-02-17T00:00:00Z","timestamp":1171670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1007\/s00431-006-0399-2","type":"journal-article","created":{"date-parts":[[2007,2,16]],"date-time":"2007-02-16T09:18:24Z","timestamp":1171617504000},"page":"1155-1161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial"],"prefix":"10.1007","volume":"166","author":[{"given":"Dieke H. J.","family":"Kok","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph J. B.","family":"Sakkers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arieke J.","family":"Janse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans E. H.","family":"Pruijs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ab J.","family":"Verbout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene M.","family":"Castelein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raoul H. H.","family":"Engelbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,2,17]]},"reference":[{"key":"399_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1080\/08035259850157895","volume":"87","author":"E Astrom","year":"1998","unstructured":"Astrom E, Soderhall S (1998) Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 87:64\u201368","journal-title":"Acta Paediatr"},{"key":"399_CR2","doi-asserted-by":"crossref","unstructured":"Bleck EE (1981) Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orthop 111\u2013122","DOI":"10.1097\/00003086-198109000-00015"},{"key":"399_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mpo.1257","volume":"38","author":"WA Bleyer","year":"2002","unstructured":"Bleyer WA (2002) Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. Med Pediatr Oncol 38:1\u201310","journal-title":"Med Pediatr Oncol"},{"key":"399_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/BF02260864","volume":"4","author":"MH Boyle","year":"1995","unstructured":"Boyle MH, Furlong W, Feeny D, Torrance GW, Hatcher J (1995) Reliability of the Health Utilities Index-Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire. Qual Life Res 4:249\u2013257","journal-title":"Qual Life Res"},{"key":"399_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/00005792-199707000-00005","volume":"76","author":"C Brumsen","year":"1997","unstructured":"Brumsen C, Hamdy NA, Papapoulos SE (1997) Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 76:266\u2013283","journal-title":"Medicine (Baltimore)"},{"key":"399_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/ajmg.1320340114","volume":"34","author":"PH Byers","year":"1989","unstructured":"Byers PH (1989) Inherited disorders of collagen gene structure and expression. Am J Med Genet 34:72\u201380","journal-title":"Am J Med Genet"},{"key":"399_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","volume":"44","author":"SC Cremers","year":"2005","unstructured":"Cremers SC, Pillai G, Papapoulos SE (2005) Pharmacokinetics\/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44:551\u2013570","journal-title":"Clin Pharmacokinet"},{"key":"399_CR8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1515\/JPEM.2005.18.1.43","volume":"18","author":"LA Dimeglio","year":"2005","unstructured":"Dimeglio LA, Ford L, McClintock C, Peacock M (2005) A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 18:43\u201353","journal-title":"J Pediatr Endocrinol Metab"},{"key":"399_CR9","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1053\/apmr.2001.23889","volume":"82","author":"RH Engelbert","year":"2001","unstructured":"Engelbert RH, Gulmans VA, Uiterwaal CS, Helders PJ (2001) Osteogenesis imperfecta in childhood: perceived competence in relation to impairment and disability. Arch Phys Med Rehabil 82:943\u2013948","journal-title":"Arch Phys Med Rehabil"},{"key":"399_CR10","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.apmr.2003.08.085","volume":"85","author":"RH Engelbert","year":"2004","unstructured":"Engelbert RH, Uiterwaal CS, Gerver WJ, van der Net JJ, Pruijs HE, Helders PJ (2004) Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with 4-year follow-up. Arch Phys Med Rehabil 85:772\u2013778","journal-title":"Arch Phys Med Rehabil"},{"key":"399_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1067\/mpd.2000.107892","volume":"137","author":"RH Engelbert","year":"2000","unstructured":"Engelbert RH, Uiterwaal CS, Gulmans VA, Pruijs H, Helders PJ (2000) Osteogenesis imperfecta in childhood: prognosis for walking. J Pediatr 137:397\u2013402","journal-title":"J Pediatr"},{"key":"399_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s004310000505","volume":"159","author":"RH Engelbert","year":"2000","unstructured":"Engelbert RH, Uiterwaal CS, Gulmans VA, Pruijs HE, Helders PJ (2000) Osteogenesis imperfecta: profiles of motor development as assessed by a postal questionnaire. Eur J Pediatr 159:615\u2013620","journal-title":"Eur J Pediatr"},{"key":"399_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1651-2227.1999.tb14364.x","volume":"88","author":"A Erling","year":"1999","unstructured":"Erling A (1999) Methodological considerations in the assessment of health-related quality of life in children. Acta Paediatr Suppl 88:106\u2013107","journal-title":"Acta Paediatr Suppl"},{"key":"399_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00005650-200202000-00006","volume":"40","author":"D Feeny","year":"2002","unstructured":"Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, Denton M, Boyle M (2002) Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 40:113\u2013128","journal-title":"Med Care"},{"key":"399_CR15","unstructured":"Furlong W et al (2005) Multiplicative multi-attribute utility function for the health utilities index mark 3 (HUI3) system: a technical report. CEHPA WP#98\u201311. Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Canada, pp 76, 96"},{"key":"399_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1477-7525-3-3","volume":"3","author":"W Furlong","year":"2005","unstructured":"Furlong W, Barr RD, Feeny D, Yandow S (2005) Patient-focused measures of functional health status and health-related quality of life in pediatric orthopedics: a case study in measurement selection. Health Qual Life Outcomes 3:3","journal-title":"Health Qual Life Outcomes"},{"key":"399_CR17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890109002092","volume":"33","author":"WJ Furlong","year":"2001","unstructured":"Furlong WJ, Feeny DH, Torrance GW, Barr RD (2001) The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 33:375\u2013384","journal-title":"Ann Med"},{"key":"399_CR18","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1359\/JBMR.041232","volume":"20","author":"D Gatti","year":"2005","unstructured":"Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L, Viapiana O, Adami S (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 20:758\u2013763","journal-title":"J Bone Miner Res"},{"key":"399_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0895-4356(95)00528-5","volume":"49","author":"RJ Gemke","year":"1996","unstructured":"Gemke RJ, Bonsel GJ (1996) Reliability and validity of a comprehensive health status measure in a heterogeneous population of children admitted to intensive care. J Clin Epidemiol 49:327\u2013333","journal-title":"J Clin Epidemiol"},{"key":"399_CR20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947\u2013952","journal-title":"N Engl J Med"},{"key":"399_CR21","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1359\/jbmr.2000.15.9.1650","volume":"15","author":"FH Glorieux","year":"2000","unstructured":"Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, Lalic L, Glorieux DF, Fassier F, Bishop NJ (2000) Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 15:1650\u20131658","journal-title":"J Bone Miner Res"},{"key":"399_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1359\/jbmr.2002.17.1.30","volume":"17","author":"FH Glorieux","year":"2002","unstructured":"Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R (2002) Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 17:30\u201338","journal-title":"J Bone Miner Res"},{"key":"399_CR23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1515\/JPEM.2001.14.5.529","volume":"14","author":"E Gonzalez","year":"2001","unstructured":"Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J (2001) Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 14:529\u2013533","journal-title":"J Pediatr Endocrinol Metab"},{"key":"399_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2307\/1129640","volume":"53","author":"S Harter","year":"1982","unstructured":"Harter S (1982) The perceived competence scale for children. Child Develop 53:87\u201397","journal-title":"Child Develop"},{"key":"399_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7525-1-54","volume":"1","author":"J Horsman","year":"2003","unstructured":"Horsman J, Furlong W, Feeny D, Torrance G (2003) The Health Utilities Index (HUI(R)): concepts, measurement properties and applications. Health Qual Life Outcomes 1:54","journal-title":"Health Qual Life Outcomes"},{"key":"399_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jclinepi.2004.09.010","volume":"58","author":"AJ Janse","year":"2005","unstructured":"Janse AJ, Uiterwaal CS, Gemke RJ, Kimpen JL, Sinnema G (2005) A difference in perception of quality of life in chronically ill children was found between parents and pediatricians. J Clin Epidemiol 58:495\u2013502","journal-title":"J Clin Epidemiol"},{"key":"399_CR27","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s004310050715","volume":"156","author":"EA Landsmeer-Beker","year":"1997","unstructured":"Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, van de Kamp JJ, Papapoulos SE (1997) Treatment of osteogenesis imperfecta with the bisphosphonate Olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr 156:792\u2013794","journal-title":"Eur J Pediatr"},{"key":"399_CR28","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2106\/00004623-199311000-00006","volume":"75","author":"A Laupacis","year":"1993","unstructured":"Laupacis A, Bourne R, Rorabeck C, Feeny D, Wong C, Tugwell P, Leslie K, Bullas R (1993) The effect of elective total hip replacement on health-related quality of life. J Bone Joint Surg Am 75:1619\u20131626","journal-title":"J Bone Joint Surg Am"},{"key":"399_CR29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2106\/00004623-198971040-00009","volume":"71","author":"A Laupacis","year":"1989","unstructured":"Laupacis A, Rorabeck CH, Bourne RB, Feeny D, Tugwell P, Sim DA (1989) Randomized trials in orthopaedics: why, how, and when? J Bone Joint Surg Am 71:535\u2013543","journal-title":"J Bone Joint Surg Am"},{"key":"399_CR30","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1359\/JBMR.050109","volume":"20","author":"AD Letocha","year":"2005","unstructured":"Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC (2005) Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20:977\u2013986","journal-title":"J Bone Miner Res"},{"key":"399_CR31","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1210\/jc.85.5.1846","volume":"85","author":"H Plotkin","year":"2000","unstructured":"Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH (2000) Pamidronate treatment of severe osteogenesis imperfecta in children under 3\u00a0years of age. J Clin Endocrinol Metab 85:1846\u20131850","journal-title":"J Clin Endocrinol Metab"},{"key":"399_CR32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.22203\/eCM.v005a04","volume":"5","author":"PJ Roughley","year":"2003","unstructured":"Roughley PJ, Rauch F, Glorieux FH (2003) Osteogenesis imperfecta-clinical and molecular diversity. Eur Cell Mater 5:41\u201347","journal-title":"Eur Cell Mater"},{"key":"399_CR33","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","volume":"363","author":"R Sakkers","year":"2004","unstructured":"Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C (2004) Skeletal effects and functional outcome with Olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363:1427\u20131431","journal-title":"Lancet"},{"key":"399_CR34","first-page":"11","volume-title":"Quality of life and pharmacoeconomics in clinical trials","author":"HS Schipper","year":"1996","unstructured":"Schipper HS, Clinch JJ, Olwenly CLM (1996) Quality of life studies: definitions and conceptual issues. In: Spilker B (ed) Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven, Philadelphia, pp 11\u201323"},{"key":"399_CR35","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0191-8869(03)00046-1","volume":"35","author":"M Shevlin","year":"2003","unstructured":"Shevlin M, Adamson G, Collins K (2003) The self-perception profile for children (SPPC): a multiple-indicator multiple-wave analysis using LISREL. Pers Indiv Differ 35:1993\u20132005","journal-title":"Pers Indiv Differ"},{"key":"399_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101\u2013116","journal-title":"J Med Genet"},{"key":"399_CR37","doi-asserted-by":"publisher","first-page":"E153","DOI":"10.1542\/peds.111.2.e153","volume":"111","author":"SJ Suskauer","year":"2003","unstructured":"Suskauer SJ, Cintas HL, Marini JC, Gerber LH (2003) Temperament and physical performance in children with osteogenesis imperfecta. Pediatrics 111:E153\u2013E161","journal-title":"Pediatrics"},{"key":"399_CR38","doi-asserted-by":"crossref","unstructured":"van Dongen-Melman JEWM, Koot HM, Verhulst FC (2001) Cross-cultural validation of Harter\u2019s self-perception profile for children in a Dutch sample. Educ Psychol Meas 739\u2013753","DOI":"10.1177\/0013164493053003018"},{"key":"399_CR39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S8756-3282(02)00790-1","volume":"31","author":"LM Ward","year":"2002","unstructured":"Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, Roughley PJ, Glorieux FH (2002) Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 31:12\u201318","journal-title":"Bone"},{"key":"399_CR40","first-page":"508","volume":"51","author":"MC Willing","year":"1992","unstructured":"Willing MC, Pruchno CJ, Atkinson M, Byers PH (1992) Osteogenesis imperfecta type I is commonly due to a COL1A1 null allele of type I collagen. Am J Hum Genet 51:508\u2013515","journal-title":"Am J Hum Genet"},{"key":"399_CR41","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1515\/JPEM.2004.17.11.1511","volume":"17","author":"M Zacharin","year":"2004","unstructured":"Zacharin M, Kanumakala S (2004) Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. J Pediatr Endocrinol Metab 17:1511\u20131517","journal-title":"J Pediatr Endocrinol Metab"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-006-0399-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-006-0399-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-006-0399-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T17:18:39Z","timestamp":1630430319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-006-0399-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,17]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1007\/s00431-006-0399-2","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,17]]},"assertion":[{"value":"26 June 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}